Outset Medical Inc. reported its first quarter 2025 financial results, highlighting a revenue increase to $29.8 million, a 6% rise from $28.2 million in the same quarter of 2024. Product revenue reached $21.3 million, showing a 4% growth from $20.4 million in the prior year. The company emphasized the strong progress in its commercial transformation and operational execution. Additionally, Outset reiterated its 2025 revenue guidance, projecting between $115 million and $125 million, with a non-GAAP gross margin expected in the high-30% range. The company also anticipates using less than $50 million in cash for 2025, a reduction from the $103 million used in 2024. CEO Leslie Trigg noted the growth in console placements and utilization-driven recurring revenue, along with the expansion of their installed base in both acute and home hemodialysis settings.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。